| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-09-16 | Vascepa® (icosapent ethyl) capsules | Amarin (USA - NJ) | Cardiovascular diseases | ||
| 2014-09-16 | fibrinogen concentrate | elective aortic surgery
|
3 | CSL Behring (Australia) | Cardiovascular diseases |
| 2014-09-16 | Fovista® | sub-retinal fibrosis in wet age-related macular degeneration (AMD) patients |
2b | Ophthotech (USA - NY) | Ophtalmological diseases |
| 2014-09-16 | AllerT | birch pollen allergy | 2b | Anergis (Switzerland) | Allergic diseases - Immunological diseases |
| 2014-09-16 | ODM-201 | castration-resistant prostate cancer (CRPC) |
3 | Bayer Healthcare (Germany) Orion Corporation (Finland) | Cancer - Oncology |
| 2014-09-16 | ALN-CC5 | complement-mediated diseases | preclinical | Alnylam Pharmaceuticals (USA - MA) | Immunological diseases |
| 2014-09-15 | Pipeline™ embolization device | unruptured intracranial aneurysms |
Covidien (Ireland) | Cardiovascular diseases - Cerebrovascular diseases | |
| 2014-09-15 | endovascular stroke devices | acute ischemic stroke |
Covidien (Ireland) | Cardiovascular diseases - Cerebrovascular diseases | |
| 2014-09-15 | Grafix® | chronic venous ulcers |
Osiris Therapeutics (USA - MD) | Cardiovascular diseases | |
| 2014-09-15 | lampalizumab | geographic atrophy (GA - advanced form of dry age-related macular degeneration (AMD) | 3 | Roche (Switzerland) | Ophtalmological diseases |
| 2014-09-15 | BI 836858 | myelodysplastic syndromesm | 2 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2014-09-15 | BI 409306 | Alzheimer's disease | 2 | Boehringer Ingelheim (Germany) | Neurodegenerative diseases |
| 2014-09-14 | ivabradine | chronic heart failure |
3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2014-09-12 | L-BLP25 - Stimuvax® (tecemotide) | unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) |
3 | Merck Serono, a Merck KGaA company (Germany) | Cancer - Oncology |
| 2014-09-12 | L-BLP25 - Stimuvax® (tecemotide) | unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC) | 3 | Merck Serono, a Merck KGaA company (Germany) | Cancer - Oncology |
| 2014-09-12 | laquinimod | relapsing-remitting multiple sclerosis (RRMS) | 2,3 | Teva Pharmaceutical Industries (Israel) Active Biotech (Sweden) | Autoimmune diseases - Neurodegenerative diseases |
| 2014-09-12 | ALN-AGT | hypertensive disorders of pregnancy (HDP), including preeclampsia |
preclinical | Alnylam Pharmaceuticals (USA - MA) | Cardiovascular diseases - Women health |
| 2014-09-11 | Plegridy™ (peginterferon beta-1a) | relapsing forms of multiple sclerosis |
3 | BiogenIdec (USA - MA) | Autoimmune diseases - Neurodegenerative diseases |
| 2014-09-11 | Tecfidera® (dimethyl fumarate) | relapsing-remitting multiple sclerosis (RRMS) |
3 | BiogenIdec (USA - MA) | Autoimmune diseases - Neurodegenerative diseases |
| 2014-09-11 | Humira® (adalimumab) | Hidradenitis Suppurativa | 3 | Abbvie (USA - IL) | Dermatological diseases - Immunological diseases |
